Chi3L1 monoclonal antibodies for therapeutic and diagnostic use

Description:

Researchers at UTHealth describe studies aimed at elucidating the underlying cellular and molecular mechanisms of hepatic platelet accumulation during acute liver injurusing murine models of acetaminophen (APAP) -induced liver injury (AILI) and concanavalin A (Con A)-induced hepatitis. To take the researchers’ findings one step further toward the clinic, they generated mouse and human anti-CHI3L1 monoclonal antibodies. These data demonstrated the feasibility of targeting CHI3L1 by a neutralizing antibody to attenuate AILI. Together, these studies provided strong evidence for the potential of targeting CHI3L1 as a novel therapeutic strategy to improve the clinical outcomes of AILI and perhaps other acute liver injury conditions as well as potential to treat cancer.

 

UTHealth Ref. No.: 2020-0033

Inventors: Dr. Zhiqiang An, Dr. Ningyan Zhang, Dr. Cynthia Ju, et. al. 

Patent Status: PCT application filed PCT/US2021/028338

License Available: world-wide, exclusive or non-exclusive

Associated Publications: eLife 2021;10:e68571 DOI: 10.7554/eLife.68571

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Biologics
Therapeutics
For Information, Contact:
Christine Flynn
Associate Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Christine.Flynn@uth.tmc.edu
Inventors:
Zhiqiang An
Changqing (Cynthia) Ju
Ningyan Zhang
Keywords:
© 2021. All Rights Reserved. Powered by Inteum